Chang T C, Wang L M, Cheng C Y, Kuo H F, Liu P C, Ho L T
Department of Medicine, Veterans General Hospital-Taipei, R.O.C.
Zhonghua Yi Xue Za Zhi (Taipei). 1990 Aug;46(2):79-85.
We evaluated the effects of gliclazide on the secretion and action of insulin in 18 non-obese (BMI 24.09 +/- 0.47 Kg/m2, range 20.89-27.52 Kg/m2) non-insulin dependent diabetic patients (mean age 56.9 +/- 1.8 years, range 39-67 years) by the oral glucose tolerance test (OGTT) and insulin suppression test (IST). Most of them were diagnosed recently and thus untreated previously. All subjects were treated with gliclazide or placebo for 3 months in a double blind cross-over design. After gliclazide therapy, fasting and 2 hour post-OGTT plasma glucose significantly decreased (136 vs. 185 mg/dl, P less than 0.005 291 vs. 358 mg/dl, P less than 0.005), 2 hours post-OGTT plasma insulin was significantly increased (79 vs. 59 uU/ml, P less than 0.05) while fasting plasma insulin remained unchanged (21 vs. 19 uU/ml, P greater than 0.1). HbAlc decreased significantly with gliclazide therapy (6.6 vs. 7.6%, P less than 0.005). In addition, oral glucose tolerance, as measured by the mean incremental areas under the plasma glucose curve, were improved significantly (1430.6 +/- 682.4 vs. 16192.5 +/- 608.5 mg.min/dl, P less than 0.005). The mean incremental areas under the plasma insulin curve during OGTT also increased (4482.0 +/- 637.1 vs. 3167.5 +/- 511.9 uU.min/ml, P less than 0.05) after gliclazide therapy. Mean steady state plasma glucose levels (SSPG) showed no remarkable difference during drug and placebo administration (188 vs. 190 mg/dl). Throughout the trial there was no significant change of body weight, nor any side effect as judged from blood counts, urinalysis, and the results of SMA-23 and EKG.(ABSTRACT TRUNCATED AT 250 WORDS)
我们通过口服葡萄糖耐量试验（OGTT）和胰岛素抑制试验（IST），评估了格列齐特对18名非肥胖（体重指数24.09±0.47 Kg/m²，范围20.89 - 27.52 Kg/m²）的非胰岛素依赖型糖尿病患者（平均年龄56.9±1.8岁，范围39 - 67岁）胰岛素分泌及作用的影响。他们中的大多数是近期确诊且此前未接受过治疗的。所有受试者均按照双盲交叉设计接受格列齐特或安慰剂治疗3个月。格列齐特治疗后，空腹及OGTT后2小时血浆葡萄糖显著降低（分别为136 vs. 185 mg/dl，P<0.005；291 vs. 358 mg/dl，P<0.005），OGTT后2小时血浆胰岛素显著升高（79 vs. 59 uU/ml，P<0.05），而空腹血浆胰岛素保持不变（21 vs. 19 uU/ml，P>0.1）。格列齐特治疗后糖化血红蛋白显著降低（6.6 vs. 7.6%，P<0.005）。此外，以血浆葡萄糖曲线下平均增量面积衡量的口服葡萄糖耐量显著改善（1430.6±682.4 vs. 16192.5±608.5 mg.min/dl，P<0.005）。格列齐特治疗后OGTT期间血浆胰岛素曲线下平均增量面积也增加（4482.0±637.1 vs. 3167.5±511.9 uU.min/ml，P<0.05）。药物及安慰剂给药期间平均稳态血浆葡萄糖水平（SSPG）无显著差异（188 vs. 190 mg/dl）。在整个试验过程中，体重无显著变化，从血细胞计数、尿液分析以及SMA - 23和心电图结果判断，也无任何副作用。（摘要截取自250字）
